• NKGen Biotech will present long-term troculeucel findings in moderate Alzheimer's disease at CTAD in Boston, Nov. 16-19, 2026.
• The single-patient analysis examines long-term cognitive benefit following Phase 1 treatment and an additional 12 months in an open-label extension.
• Poster presentation is scheduled for Nov. 16-17.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090805PRIMZONEFULLFEED9868859) on November 09, 2026, and is solely responsible for the information contained therein.